Significant progress in Xintela
Significant progress in Xintela Xintela today announces an update on the company’s development programs. Xintela develops medical products based on its patented marker technology platform XINMARK® with a focus on cell therapy and oncology. All projects have made significant progress in terms of results, patents and financing solutions so far this year. Stem cell therapy […]
Xintela extends patent protection for degenerative joint diseases
Xintela today announced that the company’s international patent application directed to the prevention and treatment of degenerative joint diseases using stem cells, including osteoarthritis, has been published. The data on which the patent application is based are derived from the horse study conducted by Xintela in late 2016. It demonstrated that stem cells, selected using […]
Newsletter no 2 2018
It is both pleasing and stimulating to look back on the intensive past six months. Our projects have shown great progress and Xintela has made significant advances. One key focus was the completion of our own GMP facility to produce stem cells for clinical trials. We opened the facility, which is located at Medicon Village […]
Xintela signs Letter of Intent with CO.DON
Xintela AB (publ) announces today that the company has signed a Letter of Intent with the leading European cell therapy company CO.DON. The parties intend to co-develop a stem cell product for the treatment of osteoarthritis, based on Xintela’s stem cell technology. CO.DON will pay an exclusivity fee for a 6- month period, during which […]
Xintela receives MUMS-status for the treatment of osteoarthritis in horses
Lund, Sweden, 28th of June 2018 – Xintela announces today that the company has received MUMS-status (Minor Use Minor Species) in Europe for the treatment of degenerative joint disease, including osteoarthritis, in horses. MUMS-status is the veterinary equivalent of Orphan Drug in human medicine. The MUMS classification gives a significant reduction of documentation requirements prior […]
Xintela Interim Report Q1 2018
Xintela’s GMP facility is completed and being prepared for production and clinical trials
Xintela AB (publ) today announced that the GMP facility is completed and that the company has moved to offices and laboratories in direct conjunction with the GMP facility. It will now be equipped with instruments and prepared for inspection and approval by the Medical Products Agency for manufacturing licenses for clinical studies. The facility is […]
Xintela develops unique methods in stem cell therapy for the brain and broadens patent portfolio
Lund, Sweden, 17th of April 2018 – Xintela AB (publ) has developed new methods for identifying and purifying neural stem cells from the brain. This opens up a completely new field within the company’s cell therapy business for the treatment of traumatic damage and diseases of the central nervous system (CNS). “We believe this has […]
Newsletter no 1 2018
In 2017, Xintela took numerous steps that enabled the company to grow into a prominent player in the field of regenerative medicine, including building its own GMP facility for stem cell production. We also broadened our product options within the cancer project by licensing human antibodies that bind to our integrin markers. Construction of our […]
Xintela prepares for oncology spinout
Xintela AB (publ) announces today that the company has decided to prepare for a possible spin-out of its oncology business into a separate company to be distributed to Xintelas existing shareholders through a stock dividend and listed on a suitable stock market during 2018. Since 2014, Xintela’s cancer project focusing on the aggressive brain tumor […]
